[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse TUBB4A

Summary
SymbolTUBB4A
Nametubulin, beta 4A class IVa
Aliases beta-5; class IVa beta-tubulin; DYT4; tubulin, beta 4; tubulin, beta 4 class IVa; dystonia 4, torsion (autos ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton.
Domain PF00091 Tubulin/FtsZ family
PF03953 Tubulin C-terminal domain
Function

Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.

> Gene Ontology
 
Biological Process GO:0000086 G2/M transition of mitotic cell cycle
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044839 cell cycle G2/M phase transition
Molecular Function GO:0003924 GTPase activity
GO:0005200 structural constituent of cytoskeleton
GO:0005525 GTP binding
GO:0019001 guanyl nucleotide binding
GO:0032561 guanyl ribonucleotide binding
Cellular Component GO:0005874 microtubule
GO:0005929 cilium
GO:0030424 axon
GO:0033267 axon part
GO:0033269 internode region of axon
GO:0043025 neuronal cell body
GO:0043209 myelin sheath
GO:0044297 cell body
GO:0044304 main axon
> KEGG and Reactome Pathway
 
KEGG hsa04145 Phagosome
hsa04540 Gap junction
Reactome R-HSA-8854518: AURKA Activation by TPX2
R-HSA-5620912: Anchoring of the basal body to the plasma membrane
R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-380287: Centrosome maturation
R-HSA-390466: Chaperonin-mediated protein folding
R-HSA-5617833: Cilium Assembly
R-HSA-389958: Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding
R-HSA-389960: Formation of tubulin folding intermediates by CCT/TriC
R-HSA-69275: G2/M Transition
R-HSA-380259: Loss of Nlp from mitotic centrosomes
R-HSA-380284: Loss of proteins required for interphase microtubule organization from the centrosome
R-HSA-392499: Metabolism of proteins
R-HSA-453274: Mitotic G2-G2/M phases
R-HSA-1852241: Organelle biogenesis and maintenance
R-HSA-389977: Post-chaperonin tubulin folding pathway
R-HSA-389957: Prefoldin mediated transfer of substrate to CCT/TriC
R-HSA-391251: Protein folding
R-HSA-380270: Recruitment of mitotic centrosome proteins and complexes
R-HSA-2565942: Regulation of PLK1 Activity at G2/M Transition
Summary
SymbolTUBB4A
Nametubulin, beta 4A class IVa
Aliases beta-5; class IVa beta-tubulin; DYT4; tubulin, beta 4; tubulin, beta 4 class IVa; dystonia 4, torsion (autos ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TUBB4A and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolTUBB4A
Nametubulin, beta 4A class IVa
Aliases beta-5; class IVa beta-tubulin; DYT4; tubulin, beta 4; tubulin, beta 4 class IVa; dystonia 4, torsion (autos ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TUBB4A in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTUBB4A
Nametubulin, beta 4A class IVa
Aliases beta-5; class IVa beta-tubulin; DYT4; tubulin, beta 4; tubulin, beta 4 class IVa; dystonia 4, torsion (autos ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TUBB4A in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5180.591
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.0690.677
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1020.962
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2590.587
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0810.935
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.480.665
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.5830.268
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0120.994
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.3160.459
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6530.566
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9430.526
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.7760.0105
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TUBB4A in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolTUBB4A
Nametubulin, beta 4A class IVa
Aliases beta-5; class IVa beta-tubulin; DYT4; tubulin, beta 4; tubulin, beta 4 class IVa; dystonia 4, torsion (autos ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TUBB4A. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTUBB4A
Nametubulin, beta 4A class IVa
Aliases beta-5; class IVa beta-tubulin; DYT4; tubulin, beta 4; tubulin, beta 4 class IVa; dystonia 4, torsion (autos ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TUBB4A. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TUBB4A.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTUBB4A
Nametubulin, beta 4A class IVa
Aliases beta-5; class IVa beta-tubulin; DYT4; tubulin, beta 4; tubulin, beta 4 class IVa; dystonia 4, torsion (autos ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TUBB4A. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTUBB4A
Nametubulin, beta 4A class IVa
Aliases beta-5; class IVa beta-tubulin; DYT4; tubulin, beta 4; tubulin, beta 4 class IVa; dystonia 4, torsion (autos ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TUBB4A expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTUBB4A
Nametubulin, beta 4A class IVa
Aliases beta-5; class IVa beta-tubulin; DYT4; tubulin, beta 4; tubulin, beta 4 class IVa; dystonia 4, torsion (autos ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TUBB4A and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTUBB4A
Nametubulin, beta 4A class IVa
Aliases beta-5; class IVa beta-tubulin; DYT4; tubulin, beta 4; tubulin, beta 4 class IVa; dystonia 4, torsion (autos ......
Chromosomal Location19p13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TUBB4A collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TUBB4A.
ID Name Drug Type Targets #Targets
DB01873Epothilone DSmall MoleculeTUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, ......11
DB03010PatupiloneSmall MoleculeTUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA4A, TUBA8, TUBB, TUBB1, TUBB3, ......11
DB05147CYT997Small MoleculeTUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2 ......14
DB06042ZEN-012Small MoleculeTOP2A, TOP2B, TUBB, TUBB1, TUBB3, TUBB4A6
DB11638ArtenimolSmall MoleculeACTG1, ALB, ALDH7A1, ALDOA, ANXA2, ATP5A1, ATP5L, ATP5O, CAST, CCT ......79